Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia
Condition(s) studied
Investigational drug(s) / intervention(s)
low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements: low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements
received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.: received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
Study summary
Objective: The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, were included into ; group (A) received low intensity laser therapy, inspiratory muscle training in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.
Eligibility
Primary outcome measure(s)
- IgG — at baseline and after one month
Immunoglobulin-G (mg/dl) - IgA — at baseline and after one month
Immunoglobulin-A(mg/dl) - IgM — at baseline and after one month
Immunoglobulin-M (mg/dl) - WBCs — at baseline and after one month
White blood cells (thousands/mm3)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Mona Mohamed Abdelkhalek | Cairo | Egypt | Recruiting |
More Badr University trials in Egypt
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07552116 on ClinicalTrials.gov ↗ ← All trials in Egypt